Combination therapy with aztreonam and clindamycin on severe infections accompanying neutropenic patients with hematological disorders
Urabe, A.; Takaku, F.; Mizoguchi, H.; Nomura, T.; Aoki, N.; Yamaguchi, H.; Mutoh, Y.; Miura, Y.; Toyama, K.; Hirashima, K.
Japanese Journal of Antibiotics 43(10): 1713-1722
1990
ISSN/ISBN: 0368-2781 PMID: 2086813 Document Number: 357101
We studied effectiveness and safety of combination therapy of aztreonam (AZT) (2 .apprx. 6 g/day) and clindamycin (CLDM) (1,200 .apprx. 2,400 mg/day) on severe infections in neutropenic patients with hematological diseases. We administered AZT and CLDM to 250 consecutive patients and analyzed the results of a total of 212 cases for evaluation except 38 cases of exclusions and dropouts. Hematological malignancies constituted the dominating underlying diseases which represented 90.6% of all underlying diseases. The overall clinical efficacy of the combination therapy with AZT and CLDM was 65.6% and the following results were obtained for different categories: sepsis, 64.7%; suspected sepsis, 66.4%; and pneumonia 54.5%. Even severe patients with less than 100/.mu.l of neutrophil counts showed good responses with an efficacy rate at 57.4%. Side effects were observed in only 7 cases (2.8%). We concluded that the combination therapy with AZT and CLDM would be useful as empiric therapy against various infections in febrile neutropenic patients with hematological diseases.